Composite Brain Tumor Endpoint Could Include Patient-Reported Outcomes
Patient-reported outcomes assessments could be developed and integrated into a composite endpoint for use in primary brain tumor clinical trials, FDA's oncology director suggested
You may also be interested in...
Patient-reported outcome instruments that measure simple concepts are not adequate to support complex claims in labeling, FDA said
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011